GLP1R and breast cancer: Moreover, GLP-1R agonists, including liraglutide, have been shown to inhibit proliferation, cell cycle progression, and/or migration in lung [13], pancreatic [31, 32], prostate [26], endometrial [15, 23], and murine colon cancer cells [38], although they were reported to promote the proliferation of breast cancer cells [14].